129 related articles for article (PubMed ID: 37960879)
41. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Horning SJ; Chao NJ; Negrin RS; Hoppe RT; Kwak LW; Long GD; Stallbaum B; O'Connor P; Blume KG
Ann Oncol; 1991 Jan; 2 Suppl 1():47-50. PubMed ID: 2043498
[TBL] [Abstract][Full Text] [Related]
42. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
[TBL] [Abstract][Full Text] [Related]
43. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
[TBL] [Abstract][Full Text] [Related]
44. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Rosenfeld CS; Przepiorka D; Schwinghammer TL; Buck DS; Bloom EJ; Shadduck RK
Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
[TBL] [Abstract][Full Text] [Related]
45. Pediatric Hodgkin's disease: treatment in the late 1990s.
Schellong G
Ann Oncol; 1998; 9 Suppl 5():S115-9. PubMed ID: 9926249
[TBL] [Abstract][Full Text] [Related]
46. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
47. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
[TBL] [Abstract][Full Text] [Related]
48. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.
Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L
Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937
[TBL] [Abstract][Full Text] [Related]
49. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
50. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Haim N; Ben-Shahar M; Epelbaum R
Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
[TBL] [Abstract][Full Text] [Related]
51. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
[TBL] [Abstract][Full Text] [Related]
52. A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study.
Zhu Y; Guo D; Kong X; Liu S; Yu C
Pharmacology; 2022; 107(1-2):69-80. PubMed ID: 34673655
[TBL] [Abstract][Full Text] [Related]
53. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
54. Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
Perren TJ; Selby PJ; Milan S; Meldrum M; McElwain TJ
Br J Cancer; 1990 Jun; 61(6):919-23. PubMed ID: 1695523
[TBL] [Abstract][Full Text] [Related]
55. Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation.
Cordero C; Loboda C; Clerc-Urmès I; Clément L; Pochon C; Chastagner P
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28696051
[TBL] [Abstract][Full Text] [Related]
56. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease.
O'Reilly SE; Klimo P; Connors JM
Cancer; 1991 Jan; 67(1 Suppl):271-80. PubMed ID: 1984827
[TBL] [Abstract][Full Text] [Related]
57.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
58. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration.
Perreault S; Baker J; Medoff E; Pratt K; Foss F; Isufi I; Seropian S; Cooper DL
Support Care Cancer; 2017 Jan; 25(1):205-208. PubMed ID: 27614867
[TBL] [Abstract][Full Text] [Related]
59. Etoposide hypersensitivity reactions associated with in-line filter use: A retrospective cohort study at CHU de Québec-Université Laval.
Dodier K; Laverdière I; Roy MJ
J Oncol Pharm Pract; 2023 Oct; 29(7):1687-1694. PubMed ID: 36544381
[TBL] [Abstract][Full Text] [Related]
60. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
